menu
    • menu

    Company profile for Sermonix Pharmaceuticals

    NEW Drugs in Dev.: 1
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sermonix Pharmaceuticals Inc is a privately held, Ohio-based biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s lead candidate is oral lasofoxifene. Lasofoxifene is currently under investigation in a phase 2 trial and is thought to be a potent third-generation selective estrogen receptor modulator (SERM) (also know...
    Sermonix Pharmaceuticals Inc is a privately held, Ohio-based biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s lead candidate is oral lasofoxifene. Lasofoxifene is currently under investigation in a phase 2 trial and is thought to be a potent third-generation selective estrogen receptor modulator (SERM) (also known as an estrogen agonist/antagonist) with high affinity for the estrogen receptor 1 (ESR1) receptor. Previous clinical development programs have suggested potential benefits to breast, bone, and vaginal tissue.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sermonix PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3000 East Main St Suite 218 Columbus, Ohio 43209
    Telephone
    Telephone
    614-864-4919
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sermonixpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sermonix & Regor Collaborate to Optimize rCARD Platform
    Sermonix & Regor Collaborate to Optimize rCARD Platform

    24 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sermonix-and-regor-announce-strategic-collaboration-to-optimize-regors-proprietary-rcard-platform-for-identification-of-novel-targets-and-therapeutics-302409362.html

    PR NEWSWIRE
    24 Mar 2025
    Share Share
    Sermonix Pharma receives Chinese approval of IND application for lasofoxifene
    Sermonix Pharma receives Chinese approval of IND application for lasofoxifene

    08 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169632&sid=2

    PHARMABIZ
    08 Jun 2024
    Share Share
    Sermonix Shares Details of Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient
    Sermonix Shares Details of Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient

    14 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/14/2516211/0/en/Sermonix-Pharmaceuticals-Shares-Details-of-First-Ever-Known-Durable-Complete-Clinical-Response-in-a-Metastatic-ER-HER2-Breast-Cancer-Patient-With-an-ESR1-Mutation-After-Prior-CDK4-.html

    GLOBENEWSWIRE
    14 Sep 2022
    Share Share
    Sermonix Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant
    Sermonix Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant

    13 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/13/2515038/0/en/Sermonix-Pharmaceuticals-Announces-Results-of-Phase-2-Study-of-Lasofoxifene-vs-Fulvestrant-in-Postmenopausal-Women-With-Locally-Advanced-or-Metastatic-ER-HER2-Breast-Cancer-and-an-.html

    GLOBENEWSWIRE
    13 Sep 2022
    Share Share
    Sermonix Pharmaceuticals Raises $40M in Series A3 Funding
    Sermonix Pharmaceuticals Raises $40M in Series A3 Funding

    27 Nov 2021

    // FINSMES

    https://www.finsmes.com/2021/11/sermonix-pharmaceuticals-raises-40m-in-series-a3-funding.html

    FINSMES
    27 Nov 2021
    Share Share
    Sermonix Project With Huntsman Cancer Institute Researcher to Investigate
    Sermonix Project With Huntsman Cancer Institute Researcher to Investigate

    21 Apr 2021

    // GLOBENEWSWIRE

    http://www.globenewswire.com/news-release/2021/04/21/2214280/0/en/Sermonix-Pharmaceuticals-Project-With-Huntsman-Cancer-Institute-Researcher-to-Investigate-Potential-Effects-of-Lasofoxifene-on-ESR1-Mutations-in-Endometrial-Cancer.html

    GLOBENEWSWIRE
    21 Apr 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search